Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Current Assets (2017 - 2025)

Dianthus Therapeutics has reported Current Assets over the past 8 years, most recently at $413.8 million for Q3 2025.

  • Quarterly results put Current Assets at $413.8 million for Q3 2025, up 43.94% from a year ago — trailing twelve months through Sep 2025 was $413.8 million (up 43.94% YoY), and the annual figure for FY2024 was $280.9 million, up 58.3%.
  • Current Assets for Q3 2025 was $413.8 million at Dianthus Therapeutics, up from $263.6 million in the prior quarter.
  • Over the last five years, Current Assets for DNTH hit a ceiling of $413.8 million in Q3 2025 and a floor of $78.6 million in Q2 2023.
  • Median Current Assets over the past 4 years was $191.5 million (2023), compared with a mean of $220.7 million.
  • Biggest five-year swings in Current Assets: tumbled 47.93% in 2023 and later soared 365.03% in 2024.
  • Dianthus Therapeutics' Current Assets stood at $82.0 million in 2022, then surged by 116.32% to $177.5 million in 2023, then skyrocketed by 58.3% to $280.9 million in 2024, then surged by 47.32% to $413.8 million in 2025.
  • The last three reported values for Current Assets were $413.8 million (Q3 2025), $263.6 million (Q2 2025), and $271.0 million (Q1 2025) per Business Quant data.